Malene Brondberg, Chief Financial Officer of Nordic Nanovector since May 2020, became Interim Chief Executive Officer of the company.
Danish Novo Nordisk is moving out of the diabetes space and taking over Prothenas ATTR amyloidosis programme – including a Phase II-ready immunotherapy.
Sanofi is shelling out US$1bn for a license granting the French pharma company access to a potential multiple myeloma treatment.
Oslo-based microbiome expert Bio-Me A/S has raised NOK10m in a new funding round.
This white paper explores the drug repurposing, where known clinical candidates or commercially approved molecules are evaluated for new targets and indications.
Dr Stefano Portolano, M.D., is the new Chief Executive Officer of Azafaros and has been appointed to the Board of Directors of the Dutch company.
French biopharma company NFL Biosciences has raised €5m following its IPO at Euronext Growth Paris.